VCYT Veracyte Inc
Company Analysis
Latest News
🟢 Veracyte rises 4.0% — Biotech Sector Rallies on Positive Clinical Data and Regulatory News
With Biotech (XBI) up 2.2%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🔴 Veracyte is trading 4.1% down with no clear catalyst
Veracyte is trading 4.1% down at $43.38 on October 12, 2026, with no clear company-specific announcement explaining the intraday drop. - Recent coverage...
🟢 Veracyte rises 4.7% — Biotech Sector Rallies on Strong IPO Debuts and M&A Activity
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a significant rally,...
🔴 Veracyte is trading 4.21% down with no confirmed company catalyst
Veracyte is trading $41.34, down 4.21%, as the softer market backdrop may be weighing on shares. - No confirmed Veracyte-specific announcement or catalyst for...
🔴 Veracyte is trading 4.46% down today amid broader market and biotech weakness
Veracyte is trading 4.46% down at $42.66, with no confirmed company-specific announcement identified to explain the October 7, 2026 decline. - Broader...
🔴 Veracyte is trading 5% down today
Veracyte is trading 4.89% lower at $45.34 on October 6, 2026, with no confirmed company announcement directly explaining the decline. - Recent coverage points...
🟢 Veracyte is trading 4.1% up today amid broader gains; direct catalyst unconfirmed
Veracyte is trading at $47.67, up 4.06%, with broader market strength the likeliest context; a direct catalyst remains unconfirmed. - No verified...
🟢 Veracyte is trading 4.03% up on October 2, 2026, amid market rebound after weaker-than-expected payrolls
Veracyte is trading at $45.97, up +4.03%, likely reflecting a broader market rebound after weaker-than-expected September payrolls eased rate-hike concerns. -...
🟢 Veracyte is trading 5% up in after-hours trading with no clear catalyst
Veracyte is trading 4.89% higher at $46.35 after-hours, with no clear catalyst identified for the rebound. - The stock closed at $44.19 on October 1, 2026,...
🔴 Veracyte is trading 4% down — catalyst remains unclear
Veracyte is trading 4.02% down at $44.19, with no clear company-specific catalyst identified for the October 1, 2026 decline. - Recent company news included...
🟢 Veracyte is trading 4.38% up today with no clear catalyst identified
Veracyte is trading 4.38% higher at $47.42 on September 28, 2026, with no clear company-specific catalyst identified for the move. - The latest reported...
🔴 Veracyte is trading 4.01% down today with no clear company-specific catalyst
Veracyte is trading 4.01% down at $46.59, with no clear company-specific catalyst identified for September 25, 2026. - Its press-release page shows no new...
🟢 Veracyte is trading 10% up today with no identified catalyst
Veracyte is trading 10.43% higher at $48.39, and the September 24, 2026 move remains unexplained. - No company-specific announcement, analyst action, or other...
🟢 Veracyte is trading 5% up today with no company-specific catalyst identified
Veracyte is trading 5.19% higher at $46.09, with no company-specific announcement or analyst action dated September 24 identified to explain the move. - It...
🔴 Veracyte is trading at 20.89% down in after-hours trading with no verified company-specific catalyst identified
Veracyte is trading 20.89% lower at $34.30 after-hours, following a September 22, 2026 close at $43.36; available coverage identifies no new company-specific...
🟢 Veracyte rises 4.2% — Biotech Sector Rallies on Major AI Collaboration Deal and Positive Clinical News
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is trading higher, driven by a...
🔴 Veracyte is trading 7.9% down in pre-market with no clear company-specific catalyst
Veracyte is trading 7.9% down at $38.25, with no clear company-specific catalyst identified for September 22, 2026. - Its latest major announcement was the...
🟢 Veracyte is trading 4.1% up today as Nasdaq rose 1.75%
Veracyte is trading 4.1% up at $41.43, most consistent with broader risk-on sentiment after the Nasdaq rose 1.75% and the S&P 500 gained 1.19%. - No new...
🟢 Veracyte rises 4.2% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🔴 Veracyte is trading 4.31% down today amid biotech-sector weakness
Veracyte is trading 4.31% down now at $38.41 as biotech shares weaken and broader markets sell off amid higher rates and persistent inflation concerns. - No...